NIAID's HIV/AIDS Research Program

Although progress has been made in the global fight against HIV/AIDS, the epidemic continues to devastate the United States and the international community with 56,300 new HIV infections each year in the U.S. and an estimated 33 million people living with HIV worldwide. As the leading U.S. government institute for HIV/AIDS research, NIAID is committed to conducting the research necessary to successfully end the fight against HIV/AIDS.

Through laboratories and clinics on the NIH campus in Bethesda, Md., and a vast network of supported research at universities, medical centers and clinical trial sites around the globe, NIAID is working to better understand HIV and how it causes disease, find new tools to prevent HIV infection including a preventive vaccine, develop new and more effective treatments for people infected with HIV, and hopefully, find a cure.

HIV/AIDS Advisory Committees

AIDS Research Advisory Committee

The AIDS Research Advisory Committee (ARAC), which consists of leading HIV scientists, advocates and community members, meets three times a year on the NIH campus in Bethesda, Md. to advise NIAID on its HIV/AIDS research programs. ARAC provides broad scientific, programmatic, and budgetary advice; reviews the status of projects managed by NIAID’s Division of AIDS; helps identify critical gaps in research; and reviews/approves all concepts for new NIAID-directed HIV/AIDS research initiatives.

AIDS Vaccine Research Subcommittee

The AIDS Vaccine Research Subcommittee (AVRS), formerly known as the AIDS Vaccine Research Working Group (AVRWG), assists NIAID in developing a comprehensive research program aimed at expediting the discovery and development of an effective HIV/AIDS vaccine. The subcommittee is composed of researchers and advocates engaged in HIV vaccine research.

The Strategic Working Group (SWG)

The Strategic Working Group (SWG) provides expert advice on the scientific priorities of the NIAID-funded HIV/AIDS Clinical Trials Networks. Specifically, the SWG serves as a forum for discussion, resolution, and proactive planning of critical issues; provides guidance on scientific priorities for future high resource trials, provides input about budget allocation for future funding of the networks and sites, and facilitates communication among all stakeholders relevant to the NIAID-sponsored HIV/AIDS Clinical Trials Networks. The SWG meets two to three times a year, and members include the network principal investigators, NIAID-appointed external advisors, representatives from the Community Partners, and the director of DAIDS.

You can leave a response, or trackback from your own site.

    Ads

    Free Domain

    CO.CC:Free Domain - www.Co.cc